AI-driven PIC™ Design
We design novel proximity-inducing compounds (PICs™), to treat diseases with high unmet medical need. Our patent-filed approach uses active machine learning to predict biomolecular interactions and generate new chemical entities.
The wholly-owned pipeline is focused on degrader development in oncology and CNS disorders, while we are open to partnerships across all indication areas.
Watch the video to learn more.
One Platform
Enables Rational PIC™ Design
CelerisTx One™






CelerisTx One™
PIC™ Design
Xanthos is the platform’s design engine. Starting with a protein target sequence, we determine 3D structures, predict ligand binding, generate linkers, predict ternary complexes and refine PIC™ selection through several layers of filters including molecular dynamics and QSAR.
From Data to Hit
Automated Synthesis Lab
Hephaistos is the platform’s synthesis engine. Machine learning-driven retrosynthesis and a robotized synthesis lab create real-world, custom chemical matter for testing in our automated biology lab (Hades). Our facility includes all necessary organic synthesis equipment, such as fume hoods, evaporators, HPLC, LC-MS and microfluidic synthesis.
From Hit to Compound
Biological Validation
Hades is the platform’s biological information engine. It generates experimental data obtained from our automated lab which we began constructing mid 2021. We exploit several, different biochemical assays and phenotypic screening protocols, and have in-house capabilities in cell culture, high-content imaging, functional assays and molecular biology.
From Compound to Lead
The PIC™ Engineering Company
We are CelerisTx
We are an international team of highly skilled experts from disciplines as computational chemistry, medicinal chemistry, biology and machine learning.
Our team is complemented by highly esteemed advisors and investors at the intersection of artificial intelligence and life sciences.
One Team. One Vision.
LEADERSHIP
Christopher Trummer
CEO, President and Co-Founder
Jakob Hohenberger
CFO/COO, Director and Co-Founder
Dr. Chris Tame
VP, Head of Drug Discovery and London Office
BOARD OF DIRECTORS
Dr. James Field
Director
Karel Kubias
Director
Dr. Peter Ho
Director
Petr Šrámek
Observer and Advisor
Dr. Ronjon Nag
Observer and Advisor
Scientific Advisors
Dr. Mark Whittaker
Former SVP Head of Protein Homeostasis at Evotec
Prof. Dr. Jean-Louis Reymond
Former Dir. of Chemistry and Biochemistry at the University of Bern.
Assoc.-Prof. Dr. Johannes Kirchmair
Head of Comp. Drug Discovery and Design at the University of Vienna.
Prof. Dr. Ola Spjuth
Professor at the University of Uppsala.
Prof. Dr. Stefan Knapp
Professor at the Goethe University Frankfurt.